NICE final guidance confirms approval of new treatment for advanced bowel cancer patients in England and Wales

We’re thrilled to see the news that the National Institute for Health and Care Excellence (NICE) has approved the use of trifluridine/tipiracil (Lonsurf) with bevacizumab (Avastin) for eligible patients living in England and Wales. 

Lonsurf, given together with Avastin, will now be available from the NHS in England and Wales to patients who have advanced bowel cancer and have already received two previous cancer treatment regimens. This option is available for those who have not been previously treated with Lonsurf, or are currently receiving Lonsurf as a solo treatment. 

We’re proud to have helped make this a reality, by providing advice to NICE on the benefits of having access to this drug combination for advanced bowel cancer patients, along with other patient groups and healthcare professionals. We'll continue to advocate for greater patient choice in bowel cancer treatments.  

The decision comes after the Scottish Medicines Consortium (SMC) approved the drug for advanced bowel cancer patients in Scotland in August.  

Dr Lisa Wilde, Director of Research and External Affairs at Bowel Cancer UK, said: “We’re delighted that NICE has approved this important drug combination for patients to access through the NHS. Bowel Cancer UK play a critical role in representing the patient voice, by championing access to the best treatment and care to help those affected by bowel cancer. 

“Sadly, advanced bowel cancer patients often face limited treatment options. Through widening their options, this decision can improve patients’ quality of life, help them cope better with the disease and possibly give them more precious time with their family and loved ones.” 

• Learn more about advanced bowel cancer   

• Find out about our campaigning work 
• Access our support